PharmiWeb.com - Global Pharma News & Resources
13-Dec-2023

Cabbacis Adds Equity Crowdfunding Platform for IPO

NIAGARA FALLS, N.Y.--(BUSINESS WIRE)--Cabbacis Inc (“Cabbacis” or the “Company”), a U.S. federally-licensed tobacco product manufacturer and plant biotech company focused on harm reduction products, announced today that investors can now participate in the Company’s Regulation A (Tier 2) initial public offering (IPO) through a capital raising portal.



The Company has strategically chosen Issuance as its Regulation A, equity crowdfunding, platform portal. The Issuance platform conveniently accepts credit cards, debit cards, American Express, Apple Pay, Google Pay, ACH (bank-to-bank), or wire transfers for investments.

Investors can now participate in the Company’s IPO on the Issuance platform at https://invest.issuance.com/cabbacis/login.

As the Company previously reported in November, the U.S. Securities and Exchange Commission (“SEC”) qualified the Company’s Form 1-A Offering Circular, up to 2,500,000 shares at $2.00 per share, which is posted on the SEC’s website at www.sec.gov/edgar/browse/?CIK=0001987010 and on the Company’s website at www.cabbacis.com/investors.

Subsequent to the closing of the Offering, Cabbacis will be applying to FINRA and OTC Markets Group to list its common stock on the OTCQB® Venture Market. Investors are encouraged to read the Offering Circular including exhibits and consult with their financial professionals prior to investing.

About Cabbacis

Cabbacis is a tobacco product manufacturer and plant biotechnology company committed to further developing and commercializing reduced nicotine cigarettes and vaporizer pods. Both types of products are predominately tobacco and include hemp. The Company’s worldwide patent portfolio includes 31 issued patents and various pending patent applications across the United States, Europe, China, Japan, South Korea, Canada, Australia, New Zealand, Mexico, Brazil and other countries — where approximately two-thirds of the world’s smokers reside. The Company holds 6 U.S. patents. Cabbacis Inc wholly owns Cabbacis LLC.

To learn more about Cabbacis, please visit www.cabbacis.com.

About Issuance

Founded in 2018, Issuance is a SaaS-based capital-raising platform utilized by issuers for regulation financings. The platform is built on a foundation of industry leadership and success, where Issuance has helped issuers raise over $300 million of growth capital. Issuance offers a streamlined mobile and desktop-friendly checkout experience that allows investors to seamlessly purchase securities of the brands they know and love.

Cautionary Note Regarding Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the federal securities law. All statements other than statements of historical or current facts made in this document are forward-looking. We identify forward-looking statements in this document by using words or phrases such as "anticipate," "believe," “consider,” "continue," "could," "estimate," "expect," “foresee,” "intend," “likely,” "may," "objective," “plan,” "potential," "plan," "predict," "project," "seek," “should,” "will" and similar words or phrases and their negatives. Forward-looking statements reflect our current expectations and are inherently uncertain. Actual outcomes or results could differ materially for a variety of reasons. Factors that could cause actual results to differ materially are described in “Risk Factors” in our Regulation A Offering Circular filed with the SEC and, when filed, our Annual Report on Form 1-K for the period ended December 31, 2023. We undertake no responsibility to publicly update or revise any forward-looking statement except as required by applicable law.


Contacts

Media
Tracy Witman
support@cabbacis.com

Editor Details

  • Company:
    • Businesswire
Last Updated: 13-Dec-2023